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Newly diagnosed follicular lymphoma is relatively common and can be effectively treated
with several differing approaches. Although the disease is often considered incurable, it
is highly responsive to therapy when indicated. This review discusses the indications for
treatment, risk stratiﬁcation systems, treatment options with supporting clinical trial data,
and expected therapeutic outcomes in newly diagnosed follicular lymphoma.
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INTRODUCTION
Follicular lymphoma is the second most common subtype of lym-
phoma with nearly 15,000 new cases annually in the United States
(Siegel et al., 2011). For unclear reasons, the incidence of FL con-
tinues to increase in the United States and Europe (Cartwright
et al., 1999; Groves et al., 2000). FL arises from germinal-center B
cells with the genetic hallmark of an acquired t(14;18) (q32;q21)
translocation, leading to deregulation of BCL2, a key gene in the
regulation of apoptosis and cell death. The t(14;18) translocation
is found in the normal B cells of over half of healthy individuals,
and thus is insufﬁcient alone for lymphomagenesis (Staudt, 2007).
Occasionally, an in situ type of FL is identiﬁed with t(14;18) and
BCL2 expression in a lymph node without other sites of disease.
Patients with in situ FL rarely progress to disseminated FL and
generally can be observed (Limpens et al., 1991; Cong et al., 2002;
Roulland et al., 2006; Staudt, 2007; Jaffe, 2009). Historically, cells
harboring the t(14;18) translocation in the peripheral blood of
healthy individuals were thought to represent naïve B cells, but
recent work suggests these cells have many similarities to FL cells,
including class-switch recombination, and surface expression of
IgM and IgD (Roulland et al., 2006). It is not clear if the pres-
ence of the t(14;18) translocation in healthy individuals has any
prognostic or therapeutic value, but suggests a possible common
pre-malignant stage.
PROGNOSTIC SYSTEMS
Nearly ﬁve of every six patients with newly diagnosed FL will
have advanced disease, either due to a long asymptomatic phase
prior to diagnosis or early dissemination. Follicular lymphoma is
staged by the Ann Arbor system, originally devised in the 1970s to
account for radiation ﬁeld size in Hodgkin lymphoma. The system
accounts for a stepwise progression to adjacent lymphnode chains,
a pattern often not found in non-Hodgkin lymphoma (NHL), and
thus its validity in this population has been questioned (Staudt and
Dave, 2005). Clinical outcomes vary within stages, suggesting that
clinical factors other than location of disease affect outcome.
In 2000, the Intergruppo Italiano Linfomi attempted to account
for these additional factors by proposing a model incorporating
age, sex, number of extranodal sites of disease, B symptoms, serum
lactate dehydrogenase (LDH), and erythrocyte sedimentation rate
(ESR; Federico et al., 2000). This model was further improved by
an international cooperative effort evaluating over 4000 patients,
creating the Follicular Lymphoma International Prognostic Index
(FLIPI,Figure 1). Based on thenumber of adverse features present,
patients were classiﬁed into three groups with 10-year overall sur-
vival (OS) rates of 70.7, 50.9, and 35.5% (Solal-Céligny et al.,
2004). The FLIPI was widely adopted, but had several important
limitations. It was created from a retrospective database analysis
of patients not treated with current chemoimmunotherapy, was
missing signiﬁcant amounts of data (ESR, β2M, and performance
status), and had an endpoint of OS. OS is difﬁcult to model in
an indolent disease such as FL due to the duration of follow-up
required, a relapsing and remitting disease course, and multi-
ple lines of effective therapy. To account for these weaknesses,
the International Follicular Lymphoma Prognostic Factor Project
launched the F2 study in 2003 (Federico et al., 2009). The primary
endpoint of the model was progression-free survival (PFS), now
the preferred metric in lymphoma clinical trials (Cheson et al.,
2007). The factors identiﬁed as signiﬁcant in the F2 study, now
referred to as the FLIPI2, are relatively similar to those included in
the FLIPI score (Figure 1). Based on the number of factors present,
the FLIPI2 classiﬁes patients into three groups with 5-year PFS of
79.5, 51.2, and 18.8%.
It is important to note that the vast majority of patient data
utilized to generate these models is from patients with grades 1
and 2 disease. Grade 3 FL is split into A and B categories by
the WHO classiﬁcation. The B category lacks centrocytes and
has similar biology and outcomes to diffuse large B cell lym-
phoma (DLBCL; Jaffe, 2009). Grade 3B FL is generally treated
like DLBCL, however this remains an area of controversy. The dis-
cussion in this paper refers to FL grades 1–3A, unless otherwise
stated.
As the majority of patients have a responding and relapsing
course, the option of not treating immediately after diagnosis,
often referred to as “watch and wait,” was explored and found to
have no detrimental effect on OS (Horning and Rosenberg, 1984;
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FIGURE 1 | Follicular lymphoma therapy indications and clinical
predictors.
O’Brien et al., 1991). More concerning, early retrospective reviews
found that multiple single agents and chemotherapy combina-
tions, though initially effective, had little or no effect on the OS
of patients with FL (Horning, 1993). Newer studies which include
therapy with targeted agents have demonstrated improvements
in survival; however cure remains elusive for the vast majority
of FL patients. Thus, newer treatments which prolong remission
duration with minimal toxicity are needed.
INDICATIONS FOR THERAPY
Most cases of FL demonstrate an indolent nature, and when
treated are highly responsive to therapy (Cheson, 2010). Nearly
all advanced FL will eventually relapse after response to initial
therapy, and thus FL is currently considered incurable in most
cases.
After appropriately staging a newly diagnosed patient with FL,
the most important initial decision is “Does this patient require
therapy now?” To assist in answering this question, several risk
stratiﬁcation classiﬁcation systems have been generated for FL.
The Groupe d’Etude des Lymphomes Folliculaires (GELF) cri-
teria (Figure 1) were developed in a prospective clinical trial
randomizing patients to observation, chemotherapy, or interferon
(Brice et al., 1997). In this trial, patients with a high tumor bur-
den had a signiﬁcantly worse OS (5-year: 78 vs. 57%). Based
on these data, patients with ≥3 nodal sites with diameters of
≥3 cm or one mass ≥7 cm are typically not candidates for delayed
therapy.
If a patient does not require immediate treatment based on the
above criteria, the options include“watch and wait,” immunother-
apy with or without chemotherapy, and or radiotherapy.
WATCH AND WAIT
Deferred therapy with serial observation, or “watch and wait,”
has been employed in asymptomatic patients with low disease
burden due to the typically indolent nature of FL, occasionally
even demonstrating regression or long periods of disease stabil-
ity without therapy (Horning and Rosenberg, 1984). Spontaneous
regressions, occurring in 5–25% patients, are thought to be related
to the immune responsive nature of FL (Kannan and Neelapu,
2009). In theGELF-86 trial, patients with newly diagnosed FLwere
randomized to receive interferon, the oral alkylating agent pred-
nimustine, or observation until clinically meaningful progression
(Brice et al., 1997). The overall response rate (ORR) to therapy
was 70 and 78% in the early treatment arms, and 70% once ther-
apy was indicated in the observation arm, and OS at 5 years was
similar in all three arms. In another immediate vs. delayed ther-
apy clinical trial, nearly 10% of the patients randomized to the
observation arm did not require systemic therapy with at least
10 years of follow-up (Ardeshna et al., 2003). Several other trials
have demonstrated similar outcomes with initial and delayed ther-
apy (Abramson et al., 2009; Kloo et al., 2011). Even with modern
therapies yielding improved survival, there are no conclusive data
yet which suggest “watch and wait” results in inferior long-term
survival outcomes.
The risk of transformation to a more aggressive form of
lymphoma is a dreaded event in FL patients, as even intensi-
ﬁcation of therapy typically results in poor outcomes with the
majority of patients dying within 2 years (Yuen et al., 1995). A
large retrospective observational study found the annual risk of
transformation to be an estimated 3% per year in patients ini-
tially treated with chemotherapy, radiotherapy, or observation
(Al-Tourah et al., 2008).
An important factor to consider with the “watch and wait”
strategy is patient anxiety. It is certainly understandable that some
patients may ﬁnd it difﬁcult to receive a diagnosis of cancer and be
given a follow-up visit in lieu of cancer therapy. Patient anxiety is
often lessenedwhenhearing the rationale behind“watch andwait,”
and the advantages of deferring exposure to potential treatment-
associated toxicities.
RADIOTHERAPY
Limited stage FL (stage I and contiguous stage II) is potentially
curable with radiotherapy alone. Several series have reported
dramatic long-term disease-free survival (35–50% at ≥10 years,
with 100% local control in the radiation ﬁeld), likely repre-
senting cure, in patients who were treated with involved ﬁeld
radiotherapy with minimal long-term toxicities (Mac Manus and
Hoppe, 1996; Wilder et al., 2001). A large trial of aggressive
chemotherapy (prior to rituximab) with 30–40 Gy involved ﬁeld
radiotherapy resulted in a 10-year time to treatment failure and
OS rates of 72 and 80%, respectively (Seymour et al., 2003). A
randomized trial is currently evaluating radiotherapy with and
without chemotherapy in this population. As neither chemother-
apy nor immunotherapy are currently able to achieve this degree
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of long-term disease control, radiotherapy is considered the stan-
dard of care and should be strongly considered in this patient
population.
IMMUNOTHERAPY
The immune responsive nature of certain malignancies, includ-
ing FL, has been successfully manipulated for therapeutic beneﬁt
using multiple strategies. In the late ninetieth century, Dr. William
Coley used a mixture of bacterial toxins as an initial attempt
at immunotherapy and reportedly achieved dramatic results in
lymphomas. Unfortunately, these results could not be replicated
(Thotathil and Jameson,2007). The immune stimulant interferon-
α demonstrated signiﬁcant activity in follicular lymphoma,
either in combination with chemotherapy or alone, but did not
have a clear impact on OS and is not commonly utilized due
to treatment related toxicities (Price et al., 1991; Solal-Celigny
et al., 1993; Solal-Céligny et al., 1998; Herold et al., 2007; Baldo
et al., 2010).
Dr. Levy and others proposed using monoclonal antibodies,
a passive immunization strategy, to target lymphoma cell surface
markers. In 1994, the phase I trial of a monoclonal antibody tar-
geting the B cell marker CD20 (IDEC-C2B8, rituximab) displayed
tumor regression in 40% of heavily pre-treated B cell lymphoma
patients (Maloney et al., 1994). The mechanism of action of rit-
uximab is thought to be a combination of complement-mediated
cytotoxicity, antibody-dependent cellular cytotoxicity, and direct
signaling. Rituximab has shown signiﬁcant single agent activ-
ity in both the frontline and relapse settings (Table 1; Maloney
et al., 1997; McLaughlin et al., 1998; Witzig et al., 2005). Impor-
tantly, these multicenter trials also found rituximab to be well
tolerated with major toxicities essentially limited to infusional
reactions.
In an attempt todirectly address“watch andwait”vs. immediate
immunotherapy, an intergroup trial randomized newly diagnosed
FL patients with stage ≥II, asymptomatic non-bulky disease to
observation, weekly rituximab × 4 doses, or weekly rituximab × 4
doses followed by maintenance rituximab (MR) every 2 months
for 2 years (Ardeshna et al., 2010). The primary endpoints were
time to initiation of new therapy and quality of life. Preliminary
results show the estimated median time to initiation of new ther-
apy was 33 months in the observation arm and not reached at 4
years in the rituximab arms. Perhaps not surprisingly, no differ-
ence in OS was found between the groups. It remains unclear
if the delay in time to initiation of new therapy achieved by
Table 1 | Clinical outcome with various therapeutic regimens in newly diagnosed FL (top) and promising experimental therapies in development
in FL (bottom).
ORR CR PFS (month) Reference
Rituximab
Previously treated 46–48 6–8 10–13 Maloney et al. (1997),
McLaughlin et al. (1998)
Untreated 72 36 26 Witzig et al. (2005)
R-CHOP 96 20 NR, 30 months = 75% Hiddemann et al. (2005)
CHOP 90 17 30 months Hiddemann et al. (2005)
BR 92.7 39.8 69.5 Rummel et al. (2012)
R-CHOP 91.3 30 31.2 Rummel et al. (2012)
R-CHOP 85 41 NR, 2 years = 76% Press et al. (2011)
CHOP-RIT 83 46 NR, 2 years = 80% Press et al. (2011)
R-lenalidomide 98 87 NR, 14 months = 94% Fowler et al. (2011)
Experimental therapies Target Current development Reference
Ibrutinib BTK Phase II Advani et al. (2012)
CAL 101 P13K Phase II de Vos et al. (2011)
ABT-263 Bcl2 Phase I/II Wilson et al. (2009)
Epratuzumab CD22 Phase II Leonard et al. (2008)
Inotuzumab CD22 Phase III Ogura et al. (2010)
SAR3419 CD19 Phase I Younes et al. (2009)
SGN-40 CD40 Phase I Advani et al. (2006)
Blinatumomab CD19/T cell Phase I Viardot et al. (2010)
Pidilizumab PD-1 Phase II Westin et al. (2010)
PF-05082566 4-1BB Phase I Fisher et al. (2012)
BiovaxID Idiotype Phase III Schuster et al. (2011)
ORR, overall response rate; CR, complete response; PFS, progression free survival; RIT, radioimmunotherapy.
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initial rituximab will ultimately change the natural history of
the disease, future responses to rituximab, or time to second line
therapy.
The PRIMA study demonstrated the value of continued expo-
sure to rituximab in a less frequent schedule, commonly referred
to as maintenance therapy (Salles et al., 2011). Over a thousand
patients with newly diagnosed FL who achieved CR or PR after
chemoimmunotherapy were randomized to observation or ritux-
imab once every 2 months. At 2 years, 75% of patients treated with
rituximab maintenance were free from progression, as opposed to
58% of observation patients (p< 0.0001). The RESORT trial ran-
domizednewly diagnosed FLpatientswho responded to rituximab
weekly× 4 to receive indeﬁniteMRor rituximab retreatment (RR)
at the time of disease progression (Kahl et al., 2011). The median
time to treatment failure was 3.9 years with MR and 3.6 with
RR, and 95% of MR and 86% of RR did not require cytotoxic
chemotherapy at 3 years. The mean number of rituximab doses
were quite different: the MR group received 15.8 (range 5–31) and
RR 4.5 (range 4–16) doses, raising the question of the cost effec-
tiveness of the maintenance approach. No difference in OS was
observed in either the PRIMA or RESORT trials.
Lenalidomide, an immunomodulatory agent that is FDA
approved to treat multiple myeloma, has recently shown very
promising efﬁcacy in both newly diagnosed and relapsed FL
(Witzig et al., 2009; Fowler et al., 2010; Zhu et al., 2011; Leonard
et al., 2012). A phase II study of lenalidomide with rituximab
in newly diagnosed FL patients revealed an impressive prelimi-
nary ORR of 98% and CR of 87% (Fowler et al., 2010, 2011). An
international randomized trial comparing rituximab with either
lenalidomide or chemotherapy in newly diagnosed FL is currently
underway.
CHEMOTHERAPY
Follicular lymphoma is a chemosensitive disease, with numerous
combinations successfully utilized over the past 30 years. A ret-
rospective review spanning 25 years from our institution found
that with each subsequent intensiﬁcation of initial therapy, both
failure-free survival (FFS) and OS improved (Liu et al., 2006). The
1972–1982 cohort was treated with cyclophosphamide, doxoru-
bicin, vincristine, prednisone (CHOP), and bleomycin, which
resulted in a 15-year FFS and OS of 13 and 27%, respectively.
In contrast, the 1988–1992 cohort was treated with intensive alter-
nating triple therapy and interferon, and achieved a 15-year FFS
and OS of 32 and 50%, respectively. Newer therapies, including
those with rituximab, had not yet reached their median FFS and
OS at the time of publication but appeared to result in further
improvements. As with any study measuring long-term outcomes
over different eras, a caveat is required for the possible inﬂu-
ence of improved supportive care and subsequent therapies on
survival.
The addition of rituximab to less intensive chemotherapy regi-
mens, including CHOP and CVP, has proven in multiple studies to
be superior to chemotherapy alone (Czuczman et al., 2004; Mar-
cus et al., 2008). A randomized trial by the German Low-Grade
Lymphoma Study Group of CHOP with or without rituximab
found superior response rates, duration of response, and OS
in the rituximab arm (Table 1; Hiddemann et al., 2005). As a
result, rituximab is now established as a core component of nearly
every therapy for FL, both as a single agent and combined with
chemotherapy.
The combination of rituximab and bendamustine, an unique
drug with activity similar to alkylating agents and purine analogs,
has demonstrated signiﬁcant activity in untreated and relapsed
FL (Table 1; Rummel et al., 2005; Cheson and Rummel, 2009).
A randomized study of rituximab combined with bendamustine
or CHOP in newly diagnosed FL reported a superior PFS of 69.5
vs. 31.2 months favoring bendamustine (Rummel et al., 2012).
Although the ﬁnal report of this trial has not been published to
date, the combination of bendamustine and rituximab is now
commonly used for newly diagnosed patients requiring therapy.
RADIOIMMUNOTHERAPY
In patients with newly diagnosed advanced stage FL treated with
CHOP chemotherapy (without rituximab), a single dose of 131I-
tositumomab resulted in an ORR of 91% and CR of 69% (Press
et al., 2006). A randomized phase III study of R-CHOP vs. CHOP
followed by 131I-tositumomab achieved similar results (2-year PFS
of 76 and 80%, OS 97 and 93%, respectively; Press et al., 2011).
An ongoing trial of R-CHOP followed by radioimmunother-
apy consolidation and MR aims to determine if efﬁcacy can be
further improved by combining multiple anti-CD20 therapeutic
modalities. A single course of 131I-tositumomab in newly diag-
nosed FL without chemotherapy resulted in an ORR of 95%, CR
of 75%, and a median PFS of 6.1 years, an approach which may be
valuable to elderly patients who fail rituximab monotherapy and
decline chemotherapy (Kaminski et al., 2005).
POST-THERAPY FOLLOW-UP
According to the NCCN guidelines, patients with initially treated
FL should be followed with physical exam and laboratory assess-
ment every 3–6 months for at least 5 years. Surveillance CT scans
should be performed no more than every 6 months for the ﬁrst
2 years, then annually if indicated. Patients and physicians may
feel more comfortable with frequent imaging, but the associated
cost and radiation exposure are not likely more advantageous than
early diagnosis of relapse in this indolent disease. When relapse is
identiﬁed, immediate therapy is not required and the same general
criteria used in newly diagnosed patients can aide in determining
when to start therapy.
If a patient appears to have relapsing disease with a rapidly
enlarging site, signiﬁcantly elevated LDH, or new B symptoms, it
is possible they have transformed into an aggressive lymphoma
(Wong and Dickinson, 2012). In this setting, it is imperative to
obtain a biopsy of the concerning site, as themost accessible lymph
node may still represent low-grade FL. Patients with FL which has
undergone transformation have a poor prognosis and should be
considered for a clinical trial.
OUTCOMES
The National LymphoCare Study evaluated treatment practices
of academic and community oncologists and found that 17%
opted for initial observation, 13.9% rituximab monotherapy,
51.9% rituximab with chemotherapy, 5.6% radiation therapy, and
only 6.1% on a clinical trial. These data were obtained prior
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to the data regarding bendamustine, and thus the majority of
chemotherapy-treated patients received R-CHOP. With the per-
ception that bendamustine has less toxicity than CHOP, these data
have likely shifted to include more use of chemotherapy overall,
with CHOP making up a smaller proportion. Of note, only 23% of
stage I patients received radiation therapy – a potentially curative
approach (see Radiation).
Newly diagnosed FL patients often are confused regarding their
long-term prognosis, as FL is often considered “incurable.” It is
important to clarify the important difference between incurable
and untreatable. Patients may read information on the Internet
and not understand this difference, and thus be unnecessar-
ily concerned or question the recommendations of their doctor.
The median OS for all newly diagnosed FL patients is >10 years,
and these data are not likely representative of modern therapy as
they are based on patients diagnosed in the pre-rituximab era (Liu
et al., 2006).
INVESTIGATIONAL APPROACHES
The LymphoCare study found that only 6.1% of patients were
enrolled on a clinical trial for newly diagnosed FL. This may
be due in part to the perception that FL is easily treated with
standard therapies that achieve satisfactory outcomes. Although
we agree with these assumptions, we recommend all newly diag-
nosed patients with FL be considered for clinical trial enrollment.
Follicular lymphoma remains an incurable disease that requires
costly, and occasionally toxic, recurrent treatments. An impres-
sive assortment of new targeted agents and immunotherapies are
undergoing clinical evaluation (Table 1; Advani et al., 2006, 2012;
Leonard et al., 2008; Wilson et al., 2009; Younes et al., 2009; Ogura
et al., 2010; Viardot et al., 2010; Westin et al., 2010; de Vos et al.,
2011; Schuster et al., 2011; Fisher et al., 2012). The ultimate deter-
mination if these potential advances can improve outcomes for
patients with FL depends upon having a signiﬁcant number of
both newly diagnosed and relapsed patients enroll on clinical
trials.
CONCLUSION
Follicular lymphoma is a common disease due to its incidence
and relatively long life expectancy. Despite it being currently
considered incurable, many effective treatments exist with many
more under evaluation. Patients with early stage disease should be
treated with radiotherapy, which is potentially curative. Newly
diagnosed advanced stage disease patients should not reﬂex-
ively be treated unless they are symptomatic or meet standard-
ized criteria. When treatment is necessary, immunotherapy or
immunochemotherapy are very effective, but eventual relapse is
common. We recommend all newly diagnosed FL patients be con-
sidered for a clinical trial to accelerate the development of the next
generation of therapy.
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